FDA raises safety questions on AstraZeneca’s bleeding reversal agentnews2024-11-19T19:37:40+00:00November 19th, 2024|Endpoints News|
BeiGene settles final suit over future Brukinsa genericsnews2024-11-19T19:17:26+00:00November 19th, 2024|Endpoints News|
Pharma telehealth programs are catching on and raising questionsnews2024-11-19T14:30:46+00:00November 19th, 2024|Endpoints News|
Pharma’s global access efforts have stalled, new report findsnews2024-11-19T13:00:59+00:00November 19th, 2024|Endpoints News|
Merck finally has subcutaneous Keytruda results, and it’s going to regulatorsnews2024-11-19T12:28:39+00:00November 19th, 2024|Endpoints News|
Synapticure raises $25M for neurodegenerative disease approachnews2024-11-19T12:00:22+00:00November 19th, 2024|Endpoints News|
Syndax’s Revuforj wins FDA approval in aggressive form of leukemianews2024-11-18T19:37:56+00:00November 18th, 2024|Endpoints News|
A rare neurological disease is Sage’s last, best hope after failures in depressionnews2024-11-18T16:22:00+00:00November 18th, 2024|Endpoints News|
Novartis strikes radiopharma deal with Ratio worth up to $745Mnews2024-11-18T13:00:29+00:00November 18th, 2024|Endpoints News|
Eisai terminates Phase 3 trial of Dravet drug lorcaserinnews2024-11-17T10:27:08+00:00November 17th, 2024|Endpoints News|
